Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lifenol is a **patented, standardized extract of female hop cones** (Humulus lupulus), rich in the phytoestrogen **8-prenylnaringenin**. It is developed as a low-dose, clinically proven dietary supplement for menopausal symptom relief and bone health. Lifenol acts by mimicking estrogenic activity, primarily attributed to prenylflavonoids such as 8-prenylnaringenin, the most potent phytoestrogen known. Randomized, double-blind, placebo-controlled clinical studies have shown that daily intake of Lifenol (85 mg) significantly reduces hot flushes, night sweats, and general menopausal discomfort, while also supporting bone mineral density in postmenopausal women. Lifenol is **100% natural, plant-based, and hormone-free**, and is well tolerated without significant side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lifenol.